Click on the icon to the right to download the 2004 Industry Symposia Brochure or review the content below for a description of all of the symposia to be offered at the 2004 Annual Meeting. (Note: You will need Adobe Acrobat Reader to view this file.)
Sponsor: AstraZeneca Pharmaceuticals
Title: PTSD and the Challenging Patient.
Program Location: Westin Chicago River North, Chicago, IL
Overview: The session will focus on challenging symptomatology and comorbidities associated with post-traumatic stress disorder (PTSD), including sleep, anxiety, depression, substance abuse, and personality disorders. We will cover evidence-based pharmacotherapy for PTSD symptoms and comorbidities with an interactive discussion of case examples at the end.
10:30 am -- 12:30 pm Symposium
12:30 pm -- 1:00 pm Lunch
Accreditation: Creative Educational Concepts, Inc. is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE # 245-000-04-010-L01 and will award 2.0 contact hours (0.2 CEUs) of credit. Statement of credit will be issued to those participants completing a CE request form and will be mailed within 10 business days.
Registration: To register for this program, please contact CEC at 1-866-360-1717 or register online at www.CEConcepts.net/CPNP.
Title: Enhancing Patient Care: Evidence Based Approaches to the Use of Atypical Antipsychotics
Program Location: The Westin Chicago River North
At the conclusion of the program, participants should be able to:
Description: The new atypical antipsychotic agents offer many advantages over the older typical agents by improving negative symptom control while also maintaining control of positive symptoms. These advantages are tempered, however, by health concerns including weight gain, increased prevalence of hyperlipidemia, and diabetes.
Recent advances in the development of atypical antipsychotics now offer clinicians new medication options that provide efficacy in relieving the positive and negative psychiatric symptoms of schizophrenia while maintaining a favorable safety and tolerability profile.
This symposium will review and compare the use of atypical antipsychotics agents in various psychotic disorders with the importance on improving the life span of people with Schizophrenia.
ACPE info: The University of Texas College of Pharmacy is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 0.2 CEUs (2 contact hours) of continuing pharmaceutical education.
Program Number #: 067-999-04-018-L01
Sponsor: Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Title: Optimizing Clinical Outcomes in the Management of Psychotic Disorders
Location: The Westin Chicago River North, Chicago, Illinois
Effective management of psychotic disorders requires consideration of the full spectrum of effects for each antipsychotic agent. Although efficacy results from clinical trials give a measure of the direct impact on psychotic symptomatology, in the real world adverse effects may influence treatment adherence and antipsychotic outcomes. In particular, the metabolic adverse effects of weight gain, hyperglycemia, and hyperlipidemia increase cardiovascular risk and impose a burden on overall patient health. This symposium will review the mechanistic evolution of antipsychotic pharmacotherapy and examine the basis for variations in efficacy and adverse effect profiles between generations and within agents of the same generation. The evolving role of antipsychotic pharmacotherapy across the spectrum of psychotic disorders will be emphasized.
After attending this symposium, participants should be better able to
The Health Science Center for Continuing Medical Education is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned the Universal Program Number 247-000-04-001-LO1 and approved for 1.5 contact hours (0.15 CEUs).
Sponsor: Eli Lilly & Company
Title: Recognition and Treatment of Bipolar Disorder across the Continuum of Care
Location: The Westin Chicago River North
Although bipolar disorder affects only 1-2% of the population, it challenges clinicians because of its cyclic and progressive nature. Over time, bipolar disorder is associated with significant morbidity and mortality. Therefore it requires that clinicians have a thorough understanding of the efficacy and safety of agents used in both short- and long-term treatment strategies. This symposium will focus on data supporting the use of standard and emerging therapies, including antipsychotics, mood stabilizers, anticonvulsants, and combination therapy. The program will conclude with an in-depth discussion of special concerns in the treatment of patients with bipolar disorder, including adherence and concomitant substance abuse.
At the conclusion of this program, attendees should be able to:
ACPE: The American Society of Health-System Pharmacists is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmacy education. The program provides 2.0 hours (0.2 CEUs) of continuing education credit.
Program Number: 204-000-04-401-L01
Sponsor: Ortho-McNeil Pharmaceutical, Inc.
Title: Advances in the Neurobiology and Treatment of Alcohol and Drug
Program Location: Astor Ballroom, The Westin Chicago River North
Overview: Alcoholism and drug dependence are associated with significant and lasting changes in brain chemistry and function. Thus, long-term abstinence following acute detoxification and withdrawal is often difficult to achieve. Recent advances in the understanding of the neurobiology of addictive disorders have laid the groundwork for new approaches to pharmacologic treatment. In particular, many antiepileptic drugs interact with neurotransmitter systems that mediate addiction, and efficacy of selected agents in controlling craving and reducing relapse has been reported. Speakers at this dinner symposium will review current knowledge of the neurobiology of alcohol and drug addiction, molecular targets in the development of new treatments, and promising investigational therapies.
Upon conclusion of this program, attendees should be able to:
Accreditation: Ernest Mario School of Pharmacy at Rutgers, The State University of New Jersey, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmaceutical education. This program is approved for 2.5 contact hours (0.25 CEUs) of continuing pharmaceutical education credit.
ACPE #: 038-999-04-003-L01